-
Archives
- June 2018
- February 2018
- May 2017
- January 2017
- December 2016
- November 2016
- October 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- March 2015
- February 2015
- September 2014
- July 2014
- January 2014
- November 2013
- July 2013
- June 2013
- April 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- June 2012
- May 2012
- March 2012
- December 2011
- November 2011
- July 2011
- March 2011
-
Meta
Author Archives: Steffan Stringer
AHPPI Attending the HRA Phase 1 Advisory Group Meeting, London, 09-Feb-2016
The National Health Service Health Research Authority (HRA) has a special interest group focusing on Phase 1 clinical trials. An excerpt from their web site: The Phase 1 Advisory Group is established by the HRA as a forum to discuss issues … Continue reading
Comments Off on AHPPI Attending the HRA Phase 1 Advisory Group Meeting, London, 09-Feb-2016
Club Phase 1 to hold it’s next meeting in Paris on 22-Mar-2016
Club Phase 1, the AHPPI’s French sister human pharmacology organisation, will be holding it’s next meeting in Paris on 22 March. The draft outline of the programme is included below: Regulatory– Update on early phase clinical trial approval & on … Continue reading
Comments Off on Club Phase 1 to hold it’s next meeting in Paris on 22-Mar-2016
Statement on the Recent Serious Adverse Events During a Clinical Trial in Europe
The European Federation for Exploratory Medicines Development (EUFEMED) yesterday posted a statement about the widely reported death and serious illnesses occurring in an exploratory clinical trial in Europe (link PRNewswire). EUFEMED is headquartered in Brussels and constitutes the federated member associations of … Continue reading
Comments Off on Statement on the Recent Serious Adverse Events During a Clinical Trial in Europe
Survey Results for AHPPI’s Annual Meeting
Steffan Stringer, published 23-Dec-2015. Correspondence steffan.stringer@alwynconsulting.co.uk. ©2015 Steffan Stringer, Alwyn Consulting, www.alwynconsulting.co.uk This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original … Continue reading
Comments Off on Survey Results for AHPPI’s Annual Meeting
Sponsors have up to 30 months after the end of a trial to publish results of Category 1 trials under EU CTR
On 05 October 2015, the EMA signed the Appendix, on disclosure rules, to the “Functional specifications for the EU portal and EU database to be audited – EMA/42176/2014”. In this document, the EMA introduces a new categorisation of clinical trials. Trials … Continue reading
Comments Off on Sponsors have up to 30 months after the end of a trial to publish results of Category 1 trials under EU CTR
Update on the implementation of the new EU Clinical Trial Regulation’s transparency rules for early phase trials
Dr Ulrike Lorch, AHPPI Chair-elect Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). The new EU Clinical Trials Regulation (EU CTR) is intended to stimulate innovation, research and development in Europe. … Continue reading
Comments Off on Update on the implementation of the new EU Clinical Trial Regulation’s transparency rules for early phase trials
Cardiac Safety – the regulatory perspective
Dr Krishna Prasad, MHRA Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). Krishna reviewed the status quo pointing out that the regulations were a success in that no drugs having undergone E14 … Continue reading
Comments Off on Cardiac Safety – the regulatory perspective
Cardiac Safety – the industry perspective
Dr Boaz Mendzelevski, BioClinica Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). This year marks the 10th anniversary of the introduction of the ICH E14 guideline which was introduced to provide … Continue reading
Comments Off on Cardiac Safety – the industry perspective
Introduction to EUFEMED & European Training Course in Human Pharmacology
Dr Jörg Täubel, EUFEMED Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). Jörg explained that the AHPPI is a founder member of EUFEMED, which was born after a long gestation on 20 … Continue reading
Comments Off on Introduction to EUFEMED & European Training Course in Human Pharmacology
Use of a Novel Risk Rating System in Early Clinical Trials
Dr Brian Leaker, Respiratory Clinical Trials. Proceedings from AHPPI’s conference on Risk Management in Early Phase Clinical Trials, 29 Oct 2015 (link). Brian outlined the structure of his unit and, in particular, the research side of the operation. The … Continue reading
Comments Off on Use of a Novel Risk Rating System in Early Clinical Trials